Vimta Labs Limited - Asset Resilience Ratio

Latest as of March 2026: 0.36%

Vimta Labs Limited (VIMTALABS) has an Asset Resilience Ratio of 0.36% as of March 2026. The Asset Resilience Ratio measures the percentage of a company's total assets that are held in liquid form (cash and short-term investments). This metric indicates how well-positioned the company is to handle unexpected financial challenges, economic downturns, or strategic opportunities without requiring external financing. See VIMTALABS net working capital ratio to evaluate short-term liquidity relative to the company's equity base.

Liquid Assets

Rs19.98 Million
≈ $216.08K USD Cash + Short-term Investments

Total Assets

Rs5.62 Billion
≈ $60.80 Million USD All company assets

Resilience Assessment

Low
Financial Resilience Level

Asset Resilience Ratio Trend (2006–2026)

This chart shows how Vimta Labs Limited's Asset Resilience Ratio has changed over time. For the complete balance sheet picture, see VIMTALABS total asset value.

Liquid Assets Composition Over Time

This chart breaks down Vimta Labs Limited's liquid assets into cash & equivalents and short-term investments, showing how the composition has evolved over time. Read VIMTALABS total debt and obligations for a breakdown of total debt and financial obligations.

Current Liquid Assets Breakdown

Component Amount % of Total Assets
Cash & Equivalents Rs0.00 0%
Short-term Investments Rs19.98 Million 0.36%
Total Liquid Assets Rs19.98 Million 0.36%

Asset Resilience Insights

  • Limited Liquidity: Vimta Labs Limited maintains only 0.36% of assets in liquid form.
  • This low level may indicate efficient asset utilization but could pose risks during economic downturns.
  • The company has significant short-term investments, indicating active treasury management.

Vimta Labs Limited Industry Peers by Asset Resilience Ratio

Compare Vimta Labs Limited's asset resilience ratio with other companies in the same industry.

Company Industry Asset Resilience Ratio
Fleury S.A.
SA:FLRY3
Diagnostics & Research 13.87%
Australian Clinical Labs Ltd
AU:ACL
Diagnostics & Research 4.11%
Healius Ltd
AU:HLS
Diagnostics & Research 0.06%
Bionet
TWO:1784
Diagnostics & Research 41.08%
Scope Fluidics SA
WAR:SCP
Diagnostics & Research 16.51%
RHYTHM Biosciences Ltd
AU:RHY
Diagnostics & Research 2.74%
Sonic Healthcare Ltd
AU:SHL
Diagnostics & Research 0.13%
Integral Diagnostics Ltd
AU:IDX
Diagnostics & Research 0.03%

Annual Asset Resilience Ratio for Vimta Labs Limited (2006–2026)

The table below shows the annual Asset Resilience Ratio data for Vimta Labs Limited.

Year Asset Resilience Ratio (%) Liquid Assets Total Assets Change
2026-03-31 0.36% Rs19.98 Million
≈ $216.08K
Rs5.62 Billion
≈ $60.80 Million
-3.26pp
2025-03-31 3.62% Rs168.85 Million
≈ $1.83 Million
Rs4.67 Billion
≈ $50.45 Million
+0.58pp
2024-03-31 3.04% Rs121.60 Million
≈ $1.32 Million
Rs4.00 Billion
≈ $43.26 Million
+0.54pp
2023-03-31 2.50% Rs90.73 Million
≈ $981.21K
Rs3.62 Billion
≈ $39.18 Million
+2.37pp
2022-03-31 0.13% Rs4.06 Million
≈ $43.91K
Rs3.07 Billion
≈ $33.22 Million
-0.01pp
2021-03-31 0.14% Rs3.92 Million
≈ $42.39K
Rs2.74 Billion
≈ $29.67 Million
-0.24pp
2020-03-31 0.38% Rs9.32 Million
≈ $100.79K
Rs2.46 Billion
≈ $26.58 Million
+0.18pp
2019-03-31 0.20% Rs4.70 Million
≈ $50.83K
Rs2.37 Billion
≈ $25.68 Million
-0.85pp
2018-03-31 1.05% Rs24.39 Million
≈ $263.77K
Rs2.32 Billion
≈ $25.12 Million
+0.58pp
2017-03-31 0.47% Rs10.45 Million
≈ $113.01K
Rs2.22 Billion
≈ $23.97 Million
+0.38pp
2011-03-31 0.09% Rs1.58 Million
≈ $17.09K
Rs1.77 Billion
≈ $19.09 Million
-12.57pp
2007-03-31 12.66% Rs220.22 Million
≈ $2.38 Million
Rs1.74 Billion
≈ $18.81 Million
-28.47pp
2006-03-31 41.13% Rs702.53 Million
≈ $7.60 Million
Rs1.71 Billion
≈ $18.47 Million
--
pp = percentage points

About Vimta Labs Limited

NSE:VIMTALABS India Diagnostics & Research
Market Cap
$289.62 Million
Rs26.78 Billion INR
Market Cap Rank
#15110 Global
#762 in India
Share Price
Rs599.30
Change (1 day)
+0.30%
52-Week Range
Rs380.70 - Rs748.20
All Time High
Rs1155.00
About

Vimta Labs Limited provides contract research and testing services in India and internationally. The company offers drug discovery, development, and drug life cycle management support services in the areas of preclinical research, clinical research, and analytical services for biopharmaceutical companies; preclinical research and testing services for medical device companies; and contract researc… Read more